Skip to main content

Table 3 Likelihood of implementation of the BPaL (Nix) regimen as standard of care

From: Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

  Overall Indonesia Kyrgyzstan Nigeria
n (%) n (%) n (%) n (%)
Implementation of BPaL as the SoC for treatment of XDR-TB and MDR-TB treatment failure/intolerance based on initial profile (Nix) Total 166 46 50 70
Likely 146 (88%) 40 (87%) 43 (86%) 63 (90%)
Neutral 18 (11%) 6 (13%) 7 (14%) 5 (7%)
Unlikely 2 (1%) 0 (0%) 0 (0%) 2 (3%)
Implementation of BPaL as SoC for treatment of Fq resistant TB without additional resistance to 2nd line injectables based on initial profile (Nix) Total 169 46 55 68
Likely 142 (84%) 38 (83%) 44 (80%) 60 (88%)
Neutral 20 (12%) 8 (17%) 10 (18%) 2 (3%)
Unlikely 7 (4%) 0 (0%) 1 (2%) 6 (9%)
  1. BPaL bedaquilline & pretomanid & linezolid, Fq fluoroquinolone, MDR multi-drug resistant, SoC standard of care, TB tuberculosis, XDR extensively drug-resistant